Astemizole in the treatment of hay fever.
A double-blind parallel trial of astemizole, pheniramine and placebo was carried out in 51 patients with hay fever. Astemizole is a new potent H1-antihistamine with long duration of action but devoid of central activity. Evaluation criteria were daily symptom- and side effect score cards, daily nasal peak flow measurements, clinical examination and blood tests. Control of nasal symptoms was significantly better with both antihistamines than with placebo. Tiredness and anticholinergic side effects were less common in the astemizole group than in the pheniramine group. No significant changes in the "safety evaluation" blood tests were observed.
D000293:Adolescent; D000328:Adult; D016589:Astemizole; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009299:Nasal Provocation Tests; D010632:Pheniramine / Q000008:administration & dosage; D010919:Placebos; D011058:Pollen / Q000276:immunology; D006255:Rhinitis, Allergic, Seasonal / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology
D001562:Benzimidazoles; D010919:Placebos; D010632:Pheniramine; D016589:Astemizole